您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版) ›› 2017, Vol. 55 ›› Issue (6): 72-76.doi: 10.6040/j.issn.1671-7554.0.2017.402

• • 上一篇    下一篇

健康管理人群高脂血症风险预测模型

张光1,王广银2,吴红彦1, 张红玉1,王停停3,4,李吉庆3,4,李敏3,4,康凤玲3,4,刘言训3,4,薛付忠3,4   

  1. 1.山东大学附属千佛山医院健康管理中心, 山东 济南 250014;2.胜利石油管理局胜利医院健康管理科, 山东 东营 257055;3.山东大学公共卫生学院生物统计学系, 山东 济南 250012;4.山东大学齐鲁生物医学大数据研究中心, 山东 济南 250012
  • 收稿日期:2017-05-06 出版日期:2017-06-10 发布日期:2017-06-10
  • 通讯作者: 王广银. E-mail:18605463543@163.com E-mail:18605463543@163.com
  • 基金资助:
    国家国际科技合作专项项目(2014DFA32830)

A prediction model of hyperlipidemia risk based on the health management population

ZHANG Guang1, WANG Guangyin2, WU Hongyan1, ZHANG Hongyu1, WANG Tingting3,4, LI Jiqing3,4, LI Min3,4, KANG Fengling3,4, LIU Yanxun3,4, XUE Fuzhong3,4   

  1. 1. Health Management Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, Shandong, China;
    2. Health Management Section, Shengli Hospital of Shandong Dongying Shengli Petroleum Administration Bureau, Dongying 257055, Shandong, China;
    3. Department of Biostatistics, School of Public Health, Shandong University, Jinan 250012, Shandong, China;
    4. Cheeloo Research Center for Biomedical Big Data, Shandong University, Jinan 250012, Shandong, China
  • Received:2017-05-06 Online:2017-06-10 Published:2017-06-10

摘要: 目的 建立20岁以上健康管理人群高脂血症风险预测模型并对其预测效果进行评价。 方法 依托山东多中心健康管理纵向观察队列共纳入30 056人,采用Cox比例风险回归建立高脂血症预测模型,利用ROC曲线下面积(AUC)进行模型评价,十折交叉验证法检验模型的预测效果和判别能力。 结果 随访期间共新发高脂血症5 063例,发病密度为47.78‰。预测模型纳入的变量为年龄、性别、吸烟、饮酒、总胆固醇、甘油三酯、总胆红素、高密度脂蛋白、糖尿病和高血压10个变量。预测模型的ROC曲线下面积AUC为0.741(95%CI: 0.731~0.752),经十折交叉验证平均AUC为0.741。 结论 构建的高脂血症风险预测模型在健康管理人群中具有较好预测能力。

关键词: 风险预测模型, 队列, 健康管理人群, 高脂血症

Abstract: Objective To construct a risk prediction model of hyperlipidemia for people aged 20 years and over. Methods A total of 30 056 people without hyperlipidemia at baseline were included based on the Shandong Multi-center Longitudinal Cohort for Health Management. The prediction model was built on Cox proportional hazards regression model. The predictability was evaluated with the area under the receiver operating characteristic(ROC)curve(AUC). The predictive effect and distinguishing ability were verified with ten-fold cross-validation. Results During the follow-up of 3.53±2.65 years, there were 5 063 new hyperlipidemia cases, and the incidence was 47.78‰. The risk factors of hyperlipidemia included age, sex, drinking, smoking, total cholesterol, triglyceride, total bilirubin, high-density lipoprotein cholesterol, diabetes and hypertension. The AUC was 0.741(95%CI:0.731-0.752). Ten-fold cross-validation verified that the AUC was 0.741. Conclusion The prediction model of hyperlipidemia has good prediction ability in the health management population.

Key words: Longitudinal cohort, Hyperlipidemia, Risk prediction model, Health management population

中图分类号: 

  • R589.2
[1] Navar-Boggan AM, Peterson ED, Dagostino RB, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease[J]. Circulation, 2015, 131(5): 451-458.
[2] Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease[J]. Prim Care, 2013, 40(1): 195-211.
[3] Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, et al. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy[J]. Rheumatol Int, 2010, 30(8): 1125-1129.
[4] Marschner IC, Colquboun D, Simes RJ, et al. Long-term risk stratification for survisors of acute coronary syndromes. Results from the long-term intervention with pravastatin in ischemic disease(LIPID)study[J]. J Am Coll Cardiol, 2001, 38(1): 56-63.
[5] Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of cholesterol-lowing treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins[J]. Lancet, 2005, 366(9493): 1267-1278.
[6] 吴兆苏, 姚崇华, 赵冬, 等. 11省市队列人群心血管疾病前瞻性研究II, 个体危险因素聚集与心血管病发病的关系[J]. 中华心血管病杂志, 2001, 29(4): 246-250. WU Zhaosu, YAO Chonghua, ZHAO Dong, et al. A prospective cohort study on cardiovascular disease incidence in 11 provinces in China. Associations between individual risk factor aggregation and cardiovascular disease incidence[J]. Chin J Cardiol, 2001, 29(4): 246-250.
[7] Zhao WH, Zhang J, Zhai Y, et al. Blood lipid profile and prevalence of dyslipidemia in Chinese adults[J]. Biomed Environ Sci, 2007, 20(4): 329-335.
[8] Erem C, Hacihasanoglu A, Deger O, et al. Prevalence of dyslipidemia andassociated risk factors among Turkish adults: Trabzon lipid study[J]. Endocrine, 2008, 34(1-3):36-51.
[9] 赵文华, 张坚, 由悦, 等. 中国18岁及以上人群血脂异常流行特点研究[J]. 中华预防医学杂志, 2005, 39(5): 306-310. ZHAO Wenhua, ZHANG Jian, YOU Yue, et al. Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China[J]. Chine Pre Med, 2005, 39(5): 306-310.
[10] 周红,德吉央宗,余光华. 87例中老年高脂血症患病情况调查[J]. 西南民族大学学报, 2011, 37(2): 246-249. ZHOU Hong, DEJIYANGZONG, YU Guanghua. A survey on 87 cases of old hyperlipidermia[J]. Journal of Southwest University for Nationalities, 2011, 37(2): 246-249.
[11] He J, Gu D, Reynolds K, et al. Serum total and lipprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China[J]. Circulation, 2004, 110(4): 405-411.
[12] Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus and cardiovascular disease: clinical implications[J]. Am J Cardiol, 2008, 102(12A): 5L-9L.
[13] Martin SS, Michos ED. Mapping hyperlipidemia in young adulthood to coronary risk: importance of cumulative exposure and how to stay young[J]. Circulation, 2015, 131(5): 445-447.
[14] Friedman JI, Tang CY, de Haas HJ, et al. Brain imaging changes associated with risk factors for cardiovascular and cerebrovascular disease in asymptomatic patients[J]. JACC Cardiovasc Imaging, 2014, 7(10): 1039-1053.
[15] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华循环杂志, 2016, 31(10): 937-953.
[16] Tietge UJ. Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis[J]. Curr Opin Lipidol, 2014, 25(1): 94-95.
[17] Hopkins AL, Lamm MG, Funk JL, et al. Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies[J]. Fitoterapia, 2013, 85: 84-94.
[18] Erem C, Hacihasanoglu A, Deger O, et al. Prevalence of dyslipidemia and associated risk factor among Turkish adults: Trabzon lipid study[J]. Endocr, 2008, 34(1-3): 36-51.
[19] 谢娟, 来则民, 黄国伟, 等. 高脂血症危险因素研究[J]. 疾病控制杂志, 2004, 4(1): 64-66. XIE Juan, LAI Zemin, HUANG Guowei, et al. Study on risk factor of hyperlipidemia[J]. Chin J Dis Control Prev, 2004, 4(1): 64-66.
[20] SU M, FU C, LI S,et al. Prevalence of hyperlipidemia and possible risk factors in rural Chinese adults: cohort study of health population in Yuhuan rural[J].Wei Sheng Yan Jiu, 2013, 42(5): 724-729.
[21] Wu JY, Duan XY, Li L, et al. Dyslipidemia in Shanghai, China[J]. Prev Med, 2010, 51(5): 412-415.
[22] Li Z, Yang R, Xu G, et al. Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing[J]. J Clin Chem,2005, 51(1): 144-150.
[23] 邵金凤,谭先娥.生活方式干预对血脂异常人群的影响[J]. 护理学杂志, 2006, 21(5): 66-67. SHAO Jinfeng, TAN Xiane. Effect of intervention about the cure of lifestyle in the blood fat abnormity crowd[J]. Journal of Nursing Science, 2006, 21(5): 66-67.
[24] Chen G, Wang H, Zhang X, et al. Nutraceuticals and functional foods in the management of hyperlipidemia[J]. Crit Rev Food Sci Nutr, 2014, 54(9): 1180-1201.
[25] Wang SH, Sun ZL, Ruan XZ, et al. Dyslipidaemia among diabetic patients with ischemic stroke in a Chinese hospital[J]. Chin Med J, 2009, 122(21): 2567-2572.
[26] Ascunce RR, Berger JS, Weintraub HS, et al. The role of statin therapy for primary prevention: what is the evidence?[J]. Curr Atheroscler Rep, 2012, 14(2): 167-174.
[27] Lauer MS, Fontanrosa PB. Updated guidelines for cholesterol management[J]. JAMA, 2001, 285(19): 2508-2509.
[1] 周苗,卞伟玮,柳晓涓,康凤玲,薛付忠,刘静. 嗜碱性粒细胞百分比与慢性肾脏病关系的回顾性队列研究[J]. 山东大学学报(医学版), 2018, 56(3): 85-90.
[2] 苏萍,杨亚超,杨洋,季加东,阿力木·达依木,李敏,薛付忠,刘言训. 健康管理人群2型糖尿病发病风险预测模型[J]. 山东大学学报(医学版), 2017, 55(6): 82-86.
[3] 李江冰,宋心红,林海燕,张冬芝,李向一,许艺博,王丽,薛付忠. 健康管理人群缺血性异常心电图的影响因素[J]. 山东大学学报(医学版), 2017, 55(6): 77-81.
[4] 王春霞,许艺博,杨宁,夏冰,王萍,薛付忠. 基于健康管理队列的冠心病风险预测模型[J]. 山东大学学报(医学版), 2017, 55(6): 66-71.
[5] 于涛,刘焕乐,冯新,徐付印,陈亚飞,薛付忠,张成琪. 基于健康管理队列的高血压风险预测模型[J]. 山东大学学报(医学版), 2017, 55(6): 61-65.
[6] 李吉庆,赵焕宗,宋炳红,张理纯,李向一,陈亚飞,王萍,薛付忠. 基于健康管理队列的心血管事件风险预测模型[J]. 山东大学学报(医学版), 2017, 55(6): 56-60.
[7] 刘娅飞,邢娉,徐秀琴,杨淑芳,刘言训,袁中尚,薛付忠. 山东多中心健康管理纵向观察队列[J]. 山东大学学报(医学版), 2017, 55(6): 30-36.
[8] 孙苑潆,杨亚超,曲明苓,陈雁敏,李敏,王淑康,薛付忠,刘云霞. 健康管理人群代谢综合征发病风险预测模型[J]. 山东大学学报(医学版), 2017, 55(6): 87-92.
[9] 李敏,王春霞,夏冰,朱茜,孙苑潆,王淑康,薛付忠,贾红英. 健康管理人群脑卒中风险预测模型[J]. 山东大学学报(医学版), 2017, 55(6): 93-97.
[10] 周苗,夏同耀,孙爱玲,李明,申振伟,卞伟玮,蒋正,康凤玲,柳晓涓,薛付忠,刘静. 健康管理人群慢性肾脏病风险预测模型[J]. 山东大学学报(医学版), 2017, 55(6): 98-103.
[11] 于媛媛,王春霞,苏萍,孙苑潆,薛付忠,刘言训. 健康管理队列白内障发病风险预测模型[J]. 山东大学学报(医学版), 2017, 55(6): 104-107.
[12] 柳晓涓,蒋正,康凤玲,周苗,林伟强,薛付忠. 中性粒细胞计数与非酒精性脂肪肝关联性的前瞻性队列研究[J]. 山东大学学报(医学版), 2017, 55(6): 119-123.
[13] 曹瑾,季晓康,孙秀彬,蒋正,薛付忠. γ-谷氨酰转肽酶与高尿酸血症关系的队列分析[J]. 山东大学学报(医学版), 2017, 55(6): 124-128.
[14] 康凤玲,丁荔洁,柳晓涓,周苗,薛付忠. 多中心健康管理人群心脑血管疾病负担分析[J]. 山东大学学报(医学版), 2017, 55(12): 51-55.
[15] 柳晓涓,丁荔洁,康凤玲,周苗,薛付忠. 健康管理人群支气管哮喘风险预测模型[J]. 山东大学学报(医学版), 2017, 55(12): 56-61.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 高立芬,孙汶生,马春红,张利宁,梁晓红,王晓燕,郭春,陈有海 . pcDNA3-HBV瞬时转染对树突状细胞的影响[J]. 山东大学学报(医学版), 2007, 45(4): 325 -328 .
[2] 肖水清,杜毅,韩晶 . 正畸治疗过程中龈沟液内细菌变化的研究[J]. 山东大学学报(医学版), 2006, 44(5): 508 -510 .
[3] 毕爱玲,高建新,刘克敬,周玉琴. 三磷酸腺苷诱导体外培养的胚胎大鼠皮层神经细胞凋亡[J]. 山东大学学报(医学版), 2006, 44(12): 1194 -1196 .
[4] 张纪庆,王志刚,丁璇,冀勇,沈寻,韩磊. 脑动静脉畸形癫痫的相关血管构筑学及栓塞治疗研究[J]. 山东大学学报(医学版), 2006, 44(12): 1238 -1240 .
[5] 王志刚,冀勇,丁璇. 动脉瘤性蛛网膜下腔出血患者血清垂体激素含量变化的动态研究[J]. 山东大学学报(医学版), 2006, 44(12): 1241 -1244 .
[6] 颜军昊,陈子江,李媛,胡京美,高姗姗. 体外受精周期中来源于单原核受精卵胚胎性染色体分析[J]. 山东大学学报(医学版), 2006, 44(6): 545 -548 .
[7] 费 玲,隋树建,任满意,许复郁,刘伟华,杜贻萌 . 实验性兔动脉粥样硬化病变中TRAIL、DR5的表达及意义[J]. 山东大学学报(医学版), 2007, 45(2): 135 -138 .
[8] 喻芳,周庚寅,张翠娟,高鹏,马超,李红. 原发性肝癌中HIF-1α、P-gp的表达及相关性的研究[J]. 山东大学学报(医学版), 2007, 45(3): 246 -249 .
[9] 赵红梅,赵蔚明,于修平,赵蕾,王红,郑燕,吕慧,李靖,刘娟,于晗. 沙眼衣原体感染对树突状细胞功能的影响[J]. 山东大学学报(医学版), 2007, 45(10): 973 -976 .
[10] 单宁宁,邹雄,张义,杨晓静,庄学伟,王洪春,侯明 . 小鼠LAK细胞MHC表达水平对其体外杀伤肿瘤活性的影响[J]. 山东大学学报(医学版), 2007, 45(11): 1096 -1100 .